Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 15,201–15,300 of 15,747
A COVID-19 Vaccines Review: What We Have Learned So Far and Where Do We Go from Here?Preprint
Wong, S. C. Y., & Morgenstern, C. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3812637
COVID-19 Vaccine Practices and Perceptions Among an Academic Healthcare Community
Prasad, S. A., Wahood, W., Rodriguez, D. N. V., et al. (2023) · Coronaviruses · doi:10.2174/0126667975259369230921054259
Fins, J. J. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0010
Hassan, A., & Prasad, D. (2022) · International Conference on Emerging Trends in Engineering and Technology (ICETET) · doi:10.1109/icetet-sip-2254415.2022.9791681
Fitz-Patrick, D., Sahgal, O., Fouche, L. F., Mitha, E., Malahleha, M., Gayed, J., Keep, G., Zhang, Y., Modjarrad, K., Belanger, T., et al. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01409-1
Self-citationSARS-CoV-2 spike antibody and T cell response in MS patients on high efficacy therapies post vaccine
Saxena, S., Zhirova, A., Krishnan, R. G., Healy, B. C., Sanon, E., Gopalakrishnan, N., Solberg, A., Conway, S. E., & Chitnis, T. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578694
Gwak, E., Choe, S., Kim, K., et al. (2025) · medRxiv · doi:10.1101/2025.04.24.25326359
Zhang, Y., Liu, X.-Z., Zhang, Z., Zhou, T., Zhang, X., Yang, H., Tan, M., Hu, N., Shi, S.-F., Wang, F., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3932259
Zeng, Q., Yang, X. Y., Gao, Q., Lin, B., Li, Y., Huang, G., & Xu, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.05.490815
“However, the clinical characteristics of non-responders to SARS-CoV-2 vaccines 119 in clinical trials remain limited.(20-24) 120”
BackgroundAltered spike dynamics drives immune evasion of SARS-CoV-2Preprint
Saksela, K., Uğurlu, H., Salminen, P., Yuan, M., Fagerlund, R., Mäkelä, A. R., Žusinaite, E., Kesti, T., Rissanen, I., Merits, A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5310668/v1
Optimal Vaccination Strategies for Multiple Dose Vaccinations
Segschneider, J., & Koster, A. M. C. A. (2022) · Lecture notes in computer science · doi:10.1007/978-3-031-18530-4_20
Jenkins, M. M., Tran, D. P., Flores, E. A., Kupferwasser, D., Pickering, H. C., Zheng, Y. Y., Gjertson, D. W., Ross, T. M., Schaenman, J. M. D., Miller, L. G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139915 · Cited by 1
“The humoral response to SARS-CoV-2 vaccination has accordingly been linked to increased protection against infection (2, 3).”
BackgroundParra-Izquierdo, V., Remolina-Granados, S. A., & Romero‐Sánchez, C. (2021) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.785
Hamad, M. A., Abed, M. N., Hamad, N. A., Abdul-Latif, M. A., Mohammed, N. A., Abdul-Razaq, A. N., & Muhammed, R. A. (2023) · UKH Journal of Science and Engineering · doi:10.25079/ukhjse.v7n1y2023.pp17-25
Hikichi, H., Fujioka, Y., Saga, A., Watanabe, K., Hasegawa, R., Moritoki, Y., & Ueki, S. (2024) · Cureus · doi:10.7759/cureus.63410 · Cited by 1
(2022) · doi:10.1101/2022.05.18.22275209
“Early studies on BNT162b2 demonstrated high vaccine efficacy against 39 COVID-19 infection after completing the full vaccination schedule [2].”
BackgroundLu, R., Liang, K.-H., Chiang, H.-L., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4141628
Vaccine Mandates: A Lesson in Technocracy and Populism
Matthews, S., & Doolittle, B. R. (2025) · Journal of Bioethical Inquiry · doi:10.1007/s11673-025-10490-z
Wang, Z., Gao, J., Bai, R., Yuan, L., Guo, H., Wang, S., Wang, Y., Wu, J., Bu, Q., Guo, H., et al. (2026) · Viruses · doi:10.3390/v18090976
Hunziker, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3794249
T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children
Vogler, I., Renken, S., Hilker, R., Lui, B. G., Finlayson, A., Gurtman, A., Sabharwal, C., Kitchin, N. R. E., Lockhart, S. P., Gruber, W. C., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf699
“We have shown in adults that two 30 µg doses of the mRNA-based coronavirus disease 2019 (COVID-19) vaccine BNT162b2 (Comirnaty ® , Pfizer/BioNTech COVID-19 vaccine) [1, 2] administered 21 days apart induced neutralizing antibodies as well as a polyepitopic T-cell response [3 , 4].”
Self-citationBhattacharya, S., Singh, A., Mehta, R., et al. (2025) · Clinical Infection in Practice · doi:10.1016/j.clinpr.2025.100507
Metabolic predictors of COVID-19 mortality and severity: A Survival AnalysisPreprint
Abdallah, A., Doudin, A., Sulaiman, T. O., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3148999/v1
de Lacerda, M. Z. E., da Silva, F. D. J. P., de Sousa, M. G., de Lima, M. Â. M., da Costa, M. G., de Souza, R. N. P., Chaves, V. L. S., & de Sousa, C. S. (2021) · Uniedusul Editora eBooks · doi:10.51324/86010749.4
Langerhans cell–targeted mRNA delivery as a skin-based strategy
Caucheteux, S. M., & Piguet, V. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.04.028
Infección posvacunación por SARS-CoV-2: impacto en la evolución clínica de la enfermedad
Alonso-Bello, C. D., Aranda-Cano, E., Otero-Leyva, J., Mondragón-Jiménez, E., Callao-Torrico, D. M., Manzano-Martínez, H. G., Chico-Juárez, C., Becerril-Mendoza, L. T., Moncayo-Coello, C. V., & Rojo-Gutiérrez, M. I. (2023) · Revista del Hospital Juárez de México · doi:10.24875/rhjm.22000058
Malino, D., Codoni, G., Kirchner, T., Engel, B., Villamil, A., Efe, C., Stättermayer, A. F., Weltzsch, J. P., Sebode, M., Bernsmeier, C., et al. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003142
Mundae, R. S., Wagley, S., Ryan, E. H., Parke, D. W., Mittra, R. A., & Tang, P. H. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.05.013
“median (interquartile range) 7 (3-14) 5 (3-14) 7 (3-21) 7 (3-21) .”
Mahmud, M. S., Kamrujjaman, M., Adan, M. M. I. Y., et al. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2109.12428
“Notably, most volunteers had these side effects after completing the final dose (Polack et al., 2020).”
BackgroundBasic Research Reveals the Unique Virologic Features of SARS-CoV-2
Uraki, R., Yamayoshi, S., & Kawaoka, Y. (2021) · TRENDS IN THE SCIENCES · doi:10.5363/tits.26.9_79
Adverse reactions following COVID-19 immunization in children of elementary school age
Yusuf, Y., Junaedi, A. A., Mutmainnah, M., Fadhilah, N. A., & Wahyuni, S. (2024) · Berita Kedokteran Masyarakat · doi:10.22146/bkm.v40i02.9712
Oral epidemiologic research utilizing big data
Matsuyama, Y. (2025) · Annals of Japan Prosthodontic Society · doi:10.2186/ajps.17.227
Tamagnini, E., Simonelli, L., Palus, M., Rezzonico-Jost, T., Lazzarini, E., Mangani, D., Hönig, V., Dvořáková, M., Arbon, D., Gambini, F., et al. (2026) · Vaccines · doi:10.3390/vaccines14070568
Hannawi, S., Villalobos, R. E., Burhan, E., Borra, M. D. L., Gupta, R. K., Aquitania, G. P., Ang, B. W., Zabat, G. M. A., Camilo C. Roa, Jr., Jesus, L. Z. D., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4689124
Wang, C., Huang, C., Jang, T., Yeh, M., Liang, P., Wei, Y., Hsu, P., Huang, C., Hsieh, M., Lin, Y., et al. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12812
“15 Therefore, the objective of this study was to investigate the anti-spike protein (anti-S) IgG response in patients with HBV infection, hepatitis C virus (HCV) infection, NAFLD, liver cirrhosis, and hepatocellular carcinoma (HCC) following the administration of a third dose of either a homologous…”
BackgroundGillot, C., Tré‐Hardy, M., Cupaiolo, R., Blairon, L., Wilmet, A., Beukinga, I., Dogné, J., Douxfils, J., & Favresse, J. (2024) · Virology · doi:10.1016/j.virol.2024.110082
Preparation of placenta-tropic mRNA lipid nanoparticles for pregnancy disorders
Swingle, K. L., & Mitchell, M. J. (2026) · Nature Protocols · doi:10.1038/s41596-025-01325-7
Vaccines for COVID-19: Effectiveness and value
McKenna, A., Rind, D. M., McQueen, R. B., et al. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.10.1313
悠, 松., 喬之, 鈴., 拓磨, 中., 明日美, 水., 雄太, 小., 琢真, 佐., & 峰司, 早. (2024) · Nihon Kyukyu Igakukai Zasshi Journal of Japanese Association for Acute Medicine · doi:10.1002/jja2.12883
Survival and Incidence of COVID-19 After SARS-CoV-2 Vaccination in a Series of 2391 Cancer PatientsPreprint
Heudel, P., Favier, B., Solodky, M.-L., Assaad, S., Chaumard, N., Trédan, O., Bachelot, T., Ray-Coquard, I. L., Russias, B., Fournier, M.-L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3968882
Selection of new COVID-19 genotypes following mass vaccination: The Rotavirus model
Lapolla, P., Familiari, P., & Bruzzaniti, P. (2022) · Vacunas · doi:10.1016/j.vacun.2021.10.004
“Other vaccines have already been shown to be effective in preventing infection.(1) Concerns arose over four variants and other nine are currently being studied.”
608 SARS-CoV-2 vaccine safety and side effects in people with SLE
Yan, L., Mendel, A., Vinet, É., Pineau, C. A., Kalache, F., Grenier, L.-P., Lee, J., Panaritis, P., & Bernatsky, S. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2022-lupus21century.29 · Cited by 1
Self-inhibiting percolation and viral spreading in epithelial tissuePreprint
Xu, X., Nielsen, B. F., & Sneppen, K. (2024) · eLife · doi:10.7554/elife.94056.1
Reports Of Autopsies In VAERS And Associated Adverse Events Linked To Cause Of DeathPreprint
Rose, J. (2024) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/a4dsz
Case Studies in Virus Detection Using Sensor Technologies
Bakhshpour, M., Gür, S. D., Ünlü, N. L., & Osman, B. (2026) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677771-00377
Were athletes at increased risk of sudden cardiac death and survived sudden cardiac arrest in 2021?
Korsgaard, S. R. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13334
Smith, D. M., Weir, I. R., Ramirez, S. I., Coelho, C. H., Manne‐Goehler, J., Aziz, M. S., Benson, C. A., Wu, X., Hyer, R. N., Dhillon, P. K., et al. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag091
Programmable Modular Peptide Nanocarriers for Targeted siRNA Delivery to Immune Cells
Kong, N., Liu, Y., Lu, L., & Wang, H. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00151
Vengalasetti, Y. V., Naderi, N., Vega, C., Kumar, A., & Catanzaro, A. T. (2022) · Wiley eBooks · doi:10.1002/9781119789741.ch6
Yoon, S. K., Phillips, A. L., Zhao, H., Yan, F., Chen, D., Zhuang, Y., Thiese, M. S., Rowley, E. A. K., Mckell, J., Yates, A., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2735182 · Cited by 1
“12,13 8 After the second dose of a primary series during these studies, fatigue was reported in 50% to 65% of participants and injection-site pain in 60% to 88% of participants.”
PLGA‐particle‐based vaccine induces SARS‐CoV‐2‐specific antibody and T‐cell responses
Horvath, D. J., Inholz, K., Mink, D., Madel, A., Koerner, J., Horlacher, R., & Basler, M. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70423 · Cited by 1
“These vaccines have been reported to effectively control infections and protect from severe COVID-19 (Baden et al., 2021; Hardt et al., 2022; Polack et al., 2020; Sadoff et al., 2021; Tregoning et al., 2021).”
SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?
Magnus, C. L., & Schmidt, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_27
A review of oral-facial side effects of covid-19 vaccines
Tabatabaei, S. F., Imani, R., Farar, B., & Rahimikhoob, M. (2024) · ̒Ulūm-i tarbiyyatī az dīdgāh-i Islām/̒Ulūm-i tarbiyyatī az dīdgāh-i Islām · doi:10.61186/jrds.21.1.78
Borkens, Y. (2022) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-022-01554-0
Mix-and-Match Vaccines to Boost a Better Immunity against Covid-19 in Jazan region
Mohammad, A., & Elhoufey, A. A. (2024) · Egyptian Journal of Health Care · doi:10.21608/ejhc.2024.343043
Niu, M., Mu, Y., Adriko, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4983466/v1
Reoccurrence of Covid-19 infection in vaccinated Iraqi community
Abdulameer, N. A., Habeeb, T. A., & Shaebth, L. J. (2023) · AIP conference proceedings · doi:10.1063/5.0135974
High-Fidelity and Cost-Effective Engineering of SARS-CoV-2
Olguin-Nava, M., Hennig, T., Börtlein, C., Bohn, P. S., Ambi, U. B., Gabel, A., Günter, L. M., Gribling-Burrer, A.-S., Schmidt, N., Caliskan, N., et al. (2025) · Viruses · doi:10.3390/v17121604
“Consequently, despite the availability of highly effective vaccines [12–14], high infection rates persist worldwide.”
Lattau, S. S. J., Dudakova, A., Kummer, K., & Zschüntzsch, J. (2022) · Der Nervenarzt · doi:10.1007/s00115-022-01363-6
2022 AOA Research Abstracts and Poster Competition
Gill, G., Palii, S. P., Arata, A., Dologmandin, M., Chiu, S., Schwarz, J., & Jones, G. M. (2022) · Journal of Osteopathic Medicine · doi:10.1515/jom-2022-2000
Klegerman, M. E., Cirillo, J. D., & McPherson, D. D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.26.441517
“1273 SARS-CoV-2 vaccines, both coding for the spike glycoprotein, developed by Pfizer-BioNTech and Moderna, respectively, elicit antibodies specific for the RBD and exhibit approximately 95% protective efficacy against SARS-CoV-2 infection (4-6).”
González, C. P. V., Vahos, J., Páez, S., Páez, M., & José Julián López, G. (2024) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v72n2.111722
Integrating Science from the Lab to Population Health
Alshuaib, S., & Alahmad, B. (2024) · Integrated science · doi:10.1007/978-3-031-64292-0_4
Goh, Y. S., Fong, S., Amrun, S. N., Lee, C. Y., Hor, P. X., Young, B. E., Chia, P. Y., Tambyah, P. A., Kalimuddin, S., Pada, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-432867/v1
Georgakopoulou, V., & Pitiriga, V. C. (2026) · Vaccines · doi:10.3390/vaccines14090812
Vaccins à ARNm contre le COVID-19 et effets indésirables cardiaques potentiels
Bernhard, B., & Grni, C. (2022) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2022.09205
Prevalência de Covid-19 em Idosos: Revisão Sistemática
de Menezes, A. L., Hurtado, J. S., Félix, K. D., Pacheco, D. F., & Xavier, S. D. S. (2021) · Uniedusul Editora eBooks · doi:10.51324/86010749.6
Nakaharai, K., Nakazawa, Y., & Yoshida, M. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.08.016
Giamarellou, H., Karavasilis, T., Sakka, V., Pechlivanidou, E., Syriopoulou, V., Dasyras, F., Michos, A. G., Spanakis, N., Karaiskos, I., Galani, L., et al. (2025) · COVID · doi:10.3390/covid5050063
“The study evaluated the rates of symptomatic and asymptomatic infections, recognizing that asymptomatic infections play a significant role in the transmission of SARS-CoV-2, providing a probable explanation for the rapid spread of the pandemic [2,14].”
InfluentialEsquenazi, A., Watanabe, T. K., Barcikowski, J., et al. (2021) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001872
Bramer, L., Hontz, R. D., Eisfeld, A. J., et al. (2022) · medRxiv · doi:10.1101/2022.04.26.22274196
“Prior efforts towards identification of protective mechanisms have focused on adaptive immunity, and clearly showed that antibodies directed against SARS-CoV-2 Spike protein neutralize virus in natural infection and vaccine recipients (10-12).”
BackgroundFDA Should Re-evaluate All mRNA Vaccines and Revoke Their Use Authorizations (The Short Version).
Wu, J. (2022) · International Journal of Coronaviruses · doi:10.14302/issn.2692-1537.ijcv-21-4053
Beck, E. C., Georgieva, M. V., de Velde, N. V., Patterson‐Lomba, O., & Mu, F. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2504627
“All six placebo-controlled RCTs identified were deemed unsuitable for the ITC, due to significant differences in study time-frames, vaccine variant formulations 16–19 , or outcomes 20,21 .”
Protective pan-betacoronavirus neutralizing antibodies by vaccinationPreprint
Zhou, P.-P., Feng, Z., He, W.-T., Zhu, Y., Yuan, M., Li, X., Zhang, Y., Vo, L., Capozzola, T., Callaghan, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.06.743418 · Cited by 2
Pecsén-Monteza, J. E., Monteza, V. P., Paredes, R. R., et al. (2022) · Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo · doi:10.35434/rcmhnaaa.2022.154.1568
Saul, A. J., Drummer, H. E., Scott, N., Spelman, T. D., Crabb, B. S., & Hellard, M. E. (2021) · medRxiv · doi:10.1101/2021.02.23.21252315
Yamamoto, K. Z., Yasuo, N., & Sekijima, M. (2021) · doi:10.33774/chemrxiv-2021-41r69-v2
Batalla, C. (2022) · Atención Primaria Práctica · doi:10.1016/j.appr.2022.100128
Zhou, J., Wang, C., Wu, Y., Zhao, B., Yang, Y., Ye, T., Zhang, K., Li, F., Hu, J., Zhang, K., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00474-9
“CircRNA was encapsulated into lipid nanoparticles (LNPs) using the NanoAssemblr Ignite platform as previously described [33, 34].”
The potential of organic nanoparticles and plant-derived adjuvants for vaccine design
Márquez-Escobar, V., Miranda-López, A., Vimolmangkang, S., & Rosales‐Mendoza, S. (2026) · Therapeutic Delivery · doi:10.1080/20415990.2026.2633967
Stolz, D. S., Luebber, F., Lange, T., Borgwardt, S., Ziemann, M., Riemekasten, G., Rupp, J., Müller‐Pinzler, L., Paulus, F. M., & Krach, S. (2022) · medRxiv · doi:10.1101/2022.04.23.22274186
Age‐related differences in mRNA vaccine immunogenicity and adjuvancy
Chinni, S. S., Trollope, G. S., Leung, P., McQualter, J. L., Tan, C. W., Wang, L., Lim, L., Wheatley, A. K., Juno, J. A., Kent, S. J., et al. (2026) · Immunology and Cell Biology · doi:10.1111/imcb.70102
The Perception of the Effectiveness of Vaccines between Myth and Reality
Jacomuzzi, A. C. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003606
Gunther, M. M., Mörl, F., & Rockenfeller, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.837287
“(1) study, although only two are explicitly set out in their main paper.”
BackgroundMethodInfluentialHoman, T., Fortunato, F., Corso, G., Lopalco, P. L., Prato, R., & Martinelli, D. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00582-9
“The administration of the first dose of the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech, Mainz, Germany) started in late 2020, and the first results of effectiveness in preventing COVID-19 infection, severe disease, and death [4] are in line with the efficacy trials [5].”
ResultZhong, Y., Chan, K. R., Tay, C. J. X., Chia, Z. W., Li, H. E., Siriphanitchakorn, T., Ong, E. Z., Leong, Y. S., Kang, A. Y. H., Chua, R. X. Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2421432/v1
Response to Second Surge, B.1.1.7 variant and UK Policy on COVID-19
Grover, J., Bhala, N. B., & Chakravorty, S. (2020) · The Physician · doi:10.38192/1.6.3.14
Patients’ approach to medicines in COVID-19
Zorlu, D., BULUT, A., Hızmalı, L., et al. (2022) · Journal of Experimental and Clinical Medicine · doi:10.52142/omujecm.39.1.21
Ferreira, N. J. S., Carvalho, R. P. R., de Oliveira, B., Raimundo, V. D., Bastos, D. S. S., Tostes, H. D. A., Lopes, S. G., Machado‐Neves, M., & Silva, E. D. A. M. D. (2026) · Journal of Parasitic Diseases · doi:10.1007/s12639-025-01900-5
Molinari, R. W. R. M., Silvério, L. D., Faria, L. F. V., Silva, V. H. R., Montevechi, L. C., & Silvério, A. D. S. D. (2025) · Journal Archives of Health · doi:10.46919/archv6n1-004
Autoimmune Disease is Associated with Heightened Risk of Long COVID but Immunization is ProtectivePreprint
Malakooti, S. K., Abboud, M., Murphy, J. E., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5068597
Adverse effect profile of COVID-19 vaccine in Northern Nigeria: a prospective observational study
Awang, S. K., Dunga, J. A., Stephen, R. I., Dika, J., Mohammad, A. S., Elijah, T. G., Vandi, Z. G., Onesimus, K. J., & Shehu, N. Y. (2025) · Annals of African Medical Research · doi:10.4081/aamr.2025.509
Örlős, Z., Miklós, Z., & Horváth, I. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.32994
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.